GW&K Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

GW&K Investment Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$58.8M	Buy	1,618,686 +142,361	+10%	+$6.36M	0.52%	56
2025 Q4	$68.7M	Buy	1,476,325 +625,779	+74%	+$27.9M	0.59%	39
2025 Q3	$35.4M	Sell	850,546 -120,264	-12%	-$3.85M	0.31%	128
2025 Q2	$27.9M	Buy	970,810 +50,790	+6%	+$1.57M	0.25%	160
2025 Q1	$30.9M	Buy	920,020 +240,897	+35%	+$9M	0.29%	142
2024 Q4	$34.7M	Sell	679,123 -53,769	-7%	-$3.01M	0.3%	136
2024 Q3	$37.5M	Buy	732,892 +355,229	+94%	+$18.3M	0.32%	128
2024 Q2	$16.9M	Sell	377,663 -10,403	-3%	-$480K	0.15%	212
2024 Q1	$18.2M	Sell	388,066 -90,997	-19%	-$3.56M	0.16%	202
2023 Q4	$17M	Sell	479,063 -3,879	-0.8%	-$119K	0.16%	197
2023 Q3	$14.4M	Sell	482,942 -102,798	-18%	-$2.12M	0.14%	204
2023 Q2	$10.6M	Buy	585,740 +48,860	+9%	+$974K	0.1%	225
2023 Q1	$8.62M	Buy	+536,880	New	+$9.94M	0.08%	227

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

GW&K Investment Management's CRNX Position: Q1 2026 in Review

GW&K Investment Management increased its Crinetics Pharmaceuticals (CRNX) stake by 9.6% in Q1 2026, buying an estimated $6.36M and bringing the position to 1,618,686 shares worth $58.8M. The position accounts for 0.52% of the portfolio, ranked #56.

GW&K Investment Management first reported a position in CRNX in Q1 2023 and has held it in 13 quarters since. The position peaked at $68.7M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

GW&K Investment Management held 1,618,686 shares of Crinetics Pharmaceuticals worth $58.8M as of Q1 2026.
GW&K Investment Management bought 142,361 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $6.36M.
Crinetics Pharmaceuticals made up 0.52% of GW&K Investment Management's portfolio in Q1 2026, its #56 holding.
GW&K Investment Management first reported a position in Crinetics Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
GW&K Investment Management's Crinetics Pharmaceuticals position peaked at $68.7M in Q4 2025.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.